Literature DB >> 18499506

Roles of TRAF molecules in B lymphocyte function.

Ping Xie1, Zachary J Kraus, Laura L Stunz, Gail A Bishop.   

Abstract

Tumor necrosis factor receptor associated factors (TRAFs) play a variety of interesting and important roles in the regulation of B lymphocyte function. They act both as cytoplasmic regulatory molecules, and as signal transducers for receptors involved in both innate and adaptive humoral immune responses. In this brief review, we highlight the current state of knowledge of the diverse roles of TRAF molecules in the functions of B lymphocytes.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18499506      PMCID： PMC2495079          DOI： 10.1016/j.cytogfr.2008.04.002

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN： 1359-6101            Impact factor:   7.638


  74 in total

Review 1.  The CD40-CD154 interaction in B cell-T cell liaisons.

Authors:  Gail A Bishop; Bruce S Hostager
Journal:  Cytokine Growth Factor Rev       Date:  2003 Jun-Aug       Impact factor: 7.638

Review 2.  The multifaceted roles of TRAFs in the regulation of B-cell function.

Authors:  Gail A Bishop
Journal:  Nat Rev Immunol       Date:  2004-10       Impact factor: 53.106

3.  IL-6 and tumor necrosis factor-alpha. Autocrine and paracrine cytokines involved in B cell function.

Authors:  P Rieckmann; F D'Alessandro; R P Nordan; A S Fauci; J H Kehrl
Journal:  J Immunol       Date:  1991-05-15       Impact factor: 5.422

4.  CD27 expression by a distinct subpopulation of human B lymphocytes.

Authors:  D Maurer; W Holter; O Majdic; G F Fischer; W Knapp
Journal:  Eur J Immunol       Date:  1990-12       Impact factor: 5.532

5.  Roles of TNF receptor-associated factor 3 in signaling to B lymphocytes by carboxyl-terminal activating regions 1 and 2 of the EBV-encoded oncoprotein latent membrane protein 1.

Authors:  Ping Xie; Gail A Bishop
Journal:  J Immunol       Date:  2004-11-01       Impact factor: 5.422

6.  Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase.

Authors:  Parameswaran Ramakrishnan; Wangxia Wang; David Wallach
Journal:  Immunity       Date:  2004-10       Impact factor: 31.745

7.  NF- kappa B2/p100 induces Bcl-2 expression.

Authors:  P Viatour; M Bentires-Alj; A Chariot; V Deregowski; L de Leval; M-P Merville; V Bours
Journal:  Leukemia       Date:  2003-07       Impact factor: 11.528

8.  Epstein-Barr virus encoded latent membrane protein 1 (LMP1) and TNF receptor associated factors (TRAF): colocalisation of LMP1 and TRAF1 in primary EBV infection and in EBV associated Hodgkin lymphoma.

Authors:  G Siegler; E Kremmer; R Gonnella; G Niedobitek
Journal:  Mol Pathol       Date:  2003-06

9.  Differential expression and function of A20 and TRAF1 in Hodgkin lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation.

Authors:  Horst Dürkop; Burkhard Hirsch; Corinna Hahn; Hans-Dieter Foss; Harald Stein
Journal:  J Pathol       Date:  2003-06       Impact factor: 7.996

10.  Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses.

Authors:  W C Sha; H C Liou; E I Tuomanen; D Baltimore
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582
View more
  19 in total

Review 1.  Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease.

Authors:  Robert C Rickert; Julia Jellusova; Ana V Miletic
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

2.  High molecular weight complex analysis of Epstein-Barr virus Latent Membrane Protein 1 (LMP-1): structural insights into LMP-1's homo-oligomerization and lipid raft association.

Authors:  Christopher M Wrobel; Timothy R Geiger; Rebecca N Nix; Aaron M Robitaille; Sandra Weigand; Alfredo Cervantes; Miguel Gonzalez; Jennifer M Martin
Journal:  Virus Res       Date:  2013-09-25       Impact factor: 3.303

3.  TNF receptor-associated factor 3 is required for T cell-mediated immunity and TCR/CD28 signaling.

Authors:  Ping Xie; Zachary J Kraus; Laura L Stunz; Yan Liu; Gail A Bishop
Journal:  J Immunol       Date:  2010-11-17       Impact factor: 5.422

4.  HOIL-1L interacting protein (HOIP) as an NF-kappaB regulating component of the CD40 signaling complex.

Authors:  Bruce S Hostager; Daniel K Fox; Douglas Whitten; Curtis G Wilkerson; Betty A Eipper; Victor P Francone; Paul B Rothman; John D Colgan
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

5.  Ubiquitin ligase Smurf1 targets TRAF family proteins for ubiquitination and degradation.

Authors:  Shan Li; Kefeng Lu; Jian Wang; Liguo An; Guiwen Yang; Hui Chen; Yu Cui; Xiushan Yin; Ping Xie; Guichun Xing; Fuchu He; Lingqiang Zhang
Journal:  Mol Cell Biochem       Date:  2009-11-24       Impact factor: 3.396

6.  TRAF binding is required for a distinct subset of in vivo B cell functions of the oncoprotein LMP1.

Authors:  Kelly M Arcipowski; Gail A Bishop
Journal:  J Immunol       Date:  2012-10-29       Impact factor: 5.422

7.  Prognostic significance of copy-number alterations in multiple myeloma.

Authors:  Hervé Avet-Loiseau; Cheng Li; Florence Magrangeas; Wilfried Gouraud; Catherine Charbonnel; Jean-Luc Harousseau; Michel Attal; Gerald Marit; Claire Mathiot; Thierry Facon; Philippe Moreau; Kenneth C Anderson; Loïc Campion; Nikhil C Munshi; Stéphane Minvielle
Journal:  J Clin Oncol       Date:  2009-08-17       Impact factor: 44.544

8.  Elevated Choline Kinase α-Mediated Choline Metabolism Supports the Prolonged Survival of TRAF3-Deficient B Lymphocytes.

Authors:  Samantha Gokhale; Wenyun Lu; Sining Zhu; Yingying Liu; Ronald P Hart; Joshua D Rabinowitz; Ping Xie
Journal:  J Immunol       Date:  2019-12-11       Impact factor: 5.422

Review 9.  ChoK-Full of Potential: Choline Kinase in B Cell and T Cell Malignancies.

Authors:  Samantha Gokhale; Ping Xie
Journal:  Pharmaceutics       Date:  2021-06-20       Impact factor: 6.321

10.  miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.

Authors:  Sonali Sharma; Gabriela Mladonicka Pavlasova; Vaclav Seda; Katerina Amruz Cerna; Eva Vojackova; Daniel Filip; Laura Ondrisova; Veronika Sandova; Lenka Kostalova; Pedro F Zeni; Marek Borsky; Jan Oppelt; Kvetoslava Liskova; Leos Kren; Andrea Janikova; Sarka Pospisilova; Stacey M Fernandes; Medhat Shehata; Laura Z Rassenti; Ulrich Jaeger; Michael Doubek; Matthew S Davids; Jennifer R Brown; Jiri Mayer; Thomas J Kipps; Marek Mraz
Journal:  Blood       Date:  2021-05-06       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.